Comment on: Drawing light from the pandemic: Rethinking strategies for health policy and beyond https://www.sciencedirect.com/science/article/pii/S0168851021002918 My view is that the pandemic highlighted the failure of public entities and they should not be further rewarded by being put in charge of… Read More »Should the fox run the hen house?
Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications… Read More »The politics of market access
It is not unreasonable to have concerns about the cost of medicines. Drug costs are usually influenced by government policies on pricing and reimbursement of medicines themselves. These range from simple discount seeking to more complex approaches such as conditional… Read More »Managerial control of medicines cost drivers
Discussions on health literacy are increasing as healthcare providers, clinicians, payers and patients consider what this means for healthcare. Having been involved in launching the world’s first digital interactive health channel in the UK in 2000, one thing I learned… Read More »9 Tribes of the Internet and their health interests
The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in… Read More »Positioning drugs in markets: how payers determine value
The AI agenda is for me all about augmenting human reasoning; what I call cognology (cognitive focus) to distinguish from technology (physical focus). This is the core challenge to work flow and adoption. Here are some thoughts on the application… Read More »A model for mapping machine learning onto human decision making